Biocryst Pharmaceuticals Inc. (BCRX) Company Profile & Statistics

Biocryst Pharmaceuticals Inc.
BCRX
(Nasdaq - US)
Closed
7.78
+0.11 (+1.43%)
in:usd•As of: Nov 08, 2024 15:59 UTC -5
Open
7.55
High
7.83
Low
7.53

About Biocryst Pharmaceuticals Inc.

CEO

Jon P. Stonehouse

Headquarters

4505 emperor boulevard,suite 200

durham, nc 27703, united states

Auditor

Ernst & Young LLP

Employees

536

Share Holders

152

Website

www.biocryst.com

Industry

biotechnology

Sector

health technology

Company Overview

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Biocryst Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization ²	1.61B
Enterprise Value	2.35B
Enterprise Value/EBITDA (ttm)	-45.56
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	3.88
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	98.54%
Operating Margin (ttm)	-28.40%
Profit Margin (ttm)	-39.37%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-39.79%
Return on Assets (ttm)	-24.06%

Income Statement

Revenue (ttm)	412.58M
Revenue Per Share (ttm)	1.99
Gross Profit (ttm)	404.85M
EBITDA (ttm)³	-51.51M
Net Income Avi to Common (ttm)	-123.82M
Diluted EPS (ttm)	-0.61

Share Statistics

Beta (5Y Monthly)	1.89
52-Week Change	42.23%
S&P500 52-Week Change	36.80%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	207.13M
Dividend Yield	0.00%
Float ⁴	196.96M
% Held by Insiders	4.80%
% Held by Institutions	85.88%

Balance Sheet

Total Cash (mrq)	330.83M
Total Cash Per Share (mrq)	1.60
Total Debt (mrq)	833.02M
Total Debt/Equity (mrq)	-176.88%
Current Ratio (mrq)	2.82%
Quick Ratio (mrq)	2.78%
Book Value Per Share (mrq)	-2.30

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.27
Free Cash Flow (ytd)	-55.44M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Biocryst Pharmaceuticals Inc.

Trade With A Regulated Broker